Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00579072 · ClinicalTrials.gov registry record

The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men With Prostate Cancer Age 65 and Older

A clinical trial of Prostate Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
230
Enrollment target
2
Study locations

NCT00579072: Active study of Prostate Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

NCT00579072 is a study of Prostate Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 230 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (62% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00579072, a study of Prostate Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
230 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to find out if therapy with hormones (such as Lupron, Casodex, Zolodex or Degarelix) change a person's thinking abilities.

Conditions Studied

Interventions

  • BEHAVIORAL Questionaires
  • DEVICE fMRI scan (optional)

Study Locations (2)

California

  • City of Hope - Duarte

New York

  • Memorial Sloan Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 230 participants
Start Date 2006-08
Est. Completion 2026-12
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the registry record for NCT00579072 still lists

NCT00579072 is an observational study that tracks outcomes without assigning an intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (62% lower).

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Questionaires is the first listed.

NCT00579072 reports a single indexed study location in California, New York.

Frequently Asked Questions

What is clinical trial NCT00579072 about?

NCT00579072 is a clinical study titled "The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men With Prostate Cancer Age 65 and Older". The purpose of this study is to find out if therapy with hormones (such as Lupron, Casodex, Zolodex or Degarelix) change a person's thinking abilities.

What is the current status of trial NCT00579072?

This trial is currently active not recruiting. The enrollment target is 230 participants. The study started on 2006-08. Estimated completion is 2026-12.

What conditions does trial NCT00579072 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT00579072?

The interventions under investigation include: Questionaires (BEHAVIORAL), fMRI scan (optional) (DEVICE).

Who is sponsoring clinical trial NCT00579072?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00579072 being conducted?

This trial has 2 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00579072's enrollment target sits among peer trials

230 198th of 735 higher than 537 of 735 other Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02710253 · 230 participants · Phase 2

    Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy

  • NCT02777879 · 230 participants

    Lung Microbiome and Inflammation in Early COPD

  • NCT03824483 · 230 participants · Phase 2

    Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

  • NCT03833622 · 230 participants · NA

    Shared Decision Making to Improve Goals of Care in the ED

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00579072, the US trial registry maintained by the National Library of Medicine. NCT00579072 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.